WallStSmart

SeaStar Medical Holding Corporation (ICU)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 4579844% more annual revenue ($65.77B vs $1.44M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

ICU

Avoid

30

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 7.3
Piotroski: 4/9

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ICU.

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ICU3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
68.9%10/10

Revenue surging 68.9% year-over-year

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

ICU4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$11.75M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-162.7%2/10

ROE of -162.7% — below average capital efficiency

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ICU

The strongest argument for ICU centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 68.9% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ICU

The primary concerns for ICU are EPS Growth, Market Cap, Profit Margin.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

ICU profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.20 — expect wider price swings.

ICU is growing revenue faster at 68.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

SeaStar Medical Holding Corporation

HEALTHCARE · BIOTECHNOLOGY · USA

SeaStar Medical Holding Corporation (ICU) is an innovative biotechnology company committed to improving treatment options for chronic kidney disease through its proprietary technologies aimed at enhancing renal function and minimizing the need for invasive procedures. Operating in a growing market with significant unmet medical needs, SeaStar is dedicated to clinical innovation and excellence. Supported by a strong research and development pipeline and strategic collaborations, the company is well-positioned to make impactful advancements in renal health and expedite the commercialization of its groundbreaking therapies.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?